Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 115 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

24%

28 trials in Phase 3/4

Results Transparency

0%

0 of 56 completed trials have results

Key Signals

25 recruiting

Enrollment Performance

Analytics

Phase 1
45(39.1%)
Phase 2
39(33.9%)
Phase 3
24(20.9%)
Phase 4
4(3.5%)
N/A
3(2.6%)
115Total
Phase 1(45)
Phase 2(39)
Phase 3(24)
Phase 4(4)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (115)

Showing 20 of 115 trials
NCT07728721Phase 2Not Yet Recruiting

Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis

Role: lead

NCT07699757Phase 1Not Yet Recruiting

HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion

Role: lead

NCT07696208Phase 4Not Yet Recruiting

Ciprofol vs Propofol for Hemodynamic Stability in Patients Having General Anesthesia for Endovascular Thrombectomy After Ischemic Stroke

Role: collaborator

NCT07695142Phase 1Not Yet Recruiting

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid Tumors

Role: lead

NCT07566663Not ApplicableRecruiting

Preventive Analgesia With Anrikefon in Laparoscopic Cholecystectomy

Role: collaborator

NCT07580794Phase 1Recruiting

First-in-human Study of HSK56630 in Healthy Subjects

Role: lead

NCT06168383Phase 2Completed

To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .

Role: lead

NCT07658339Phase 3Not Yet Recruiting

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD

Role: lead

NCT07581951Phase 3Not Yet Recruiting

A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH

Role: lead

NCT07583849Phase 3Recruiting

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD

Role: lead

NCT07140328Phase 2Recruiting

Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Role: lead

NCT07623486Phase 1Active Not Recruiting

Trial of HSK44459 Cream for the Management Plaque Psoriasis

Role: lead

NCT07634367Phase 3Not Yet Recruiting

Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD

Role: lead

NCT07616375Phase 3Recruiting

A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis

Role: lead

NCT07616700Phase 2Recruiting

A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy

Role: lead

NCT07533786Phase 2Recruiting

A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery

Role: lead

NCT07390123Phase 3Recruiting

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

Role: lead

NCT06670352Phase 2Completed

Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

Role: lead

NCT07561554Phase 1Recruiting

Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation

Role: lead

NCT07558967Phase 1Completed

Bioequivalence Study of Tenofovir Disoproxil Fumarate Tablets in Healthy Chinese Subjects

Role: lead